Drugs / RX001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06934590 | May 2025 → Sep 2026 overdue | non-small cell lung carcinoma | GeneCraft Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RX001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06934590 ↗ |
| Known as | AAV-hRUNX3 | “Subjects will receive a single RX001 (AAV-hRUNX3) treatment via Intra-tumoral injection” NCT06934590 ↗ |
| Route | Other | “via Intra-tumoral injection” NCT06934590 ↗ |